Fu DJ
Johnson & Johnson, NJ, United States.
ArticleKetamine
Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].
ArticleKetamine
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
ArticleKetamine
Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.
ArticleKetamine
Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.
ArticleKetamine
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science.
ArticleKetamine
Esketamine for Treatment-Resistant Depression-Reply.
ArticleKetamine
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
ArticleKetamine
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.
ArticleKetamine
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.
ArticleKetamine
Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.
ArticleKetamine
A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics.
ArticleKetamine
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study).
ArticleKetamine